Search

Displaying results 511 - 520 of 5383 in total
  1. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of … [L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.[L49555]

  2. Drug

    Elasomeran

    go.drugbank.com/drugs/DB15654
    ApprovedInvestigational

    [L28026] On December 18, 2020, the FDA first issued an emergency use authorization (EUA) for the Moderna COVID-19 Vaccine as the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in … [L39217] The Moderna COVID-19 Vaccine was fully approved by the FDA on January 31, 2022 [L40079] and Health Canada expanded the use of the Moderna COVID-19 Vaccine to include individuals aged six to 11

  3. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses.

  4. Drug

    Hydroxycitronellal

    go.drugbank.com/drugs/DB14187
    Approved

    Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain

    Mixtures: Test Thin-Layer Rapid Use Patch Test
  5. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment. … Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for

  6. Drug

    Fenproporex

    go.drugbank.com/drugs/DB01550
    ApprovedIllicitWithdrawn

    In 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers. … the FDA for clinical use due to a lack of efficacy and safety data, and is listed as a drug in Schedule IV of the Controlled Substances Act.

  7. Drug

    Piperazine

    go.drugbank.com/drugs/DB00592
    ApprovedVet approvedWithdrawn

    First used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953. … Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful.

  8. Drug

    Loratadine

    go.drugbank.com/drugs/DB00455
    ApprovedInvestigational

    Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st genera...

    Categories: Antihistamines for Systemic UseProducts: ALLOR (LORATADINE ORAL SOLUTION 5MG/5ML USP)
  9. Drug

    Carbinoxamine

    go.drugbank.com/drugs/DB00748
    Approved

    This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. … The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many

    Categories: Antihistamines for Systemic Use
  10. Drug

    Gadodiamide

    go.drugbank.com/drugs/DB00225
    ApprovedInvestigational

    [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used.